TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy~* 7.0 % =\< HbA1c \< 10.0 %~* Body Mass Index (BMI) \< 30.0 kg/m\^2~Exclusion Criteria:~* Subjects treated with thiazolidinediones or insulin~* Subjects with any serious medical conditions

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant~* Age ≥ 16 years~* Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options~* Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~Exclusion Criteria:~* Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy~* Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration~* CD19 negative B-cell leukaemia~* Burkitt cell or mixed lineage acute leukaemia

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- UCART19 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Spice Consumption on the Microbiome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy human adults age 18-65 years old~* Typically consume low fiber/polyphenol diet (beige diet)-~Exclusion Criteria:~* Eating a high fiber/polyphenol diet or taking any medication or dietary supplement which interfere with the absorption of polyphenols.~* History of gastrointestinal surgery, diabetes mellitus, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP \>160mmHg, diastolic BP \> 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.~* Pregnant or breastfeeding~* Currently uses tobacco products.~* Is unable or unwilling to comply with the study protocol.~* Frequently using prebiotics, probiotics, yogurt, and/or any fiber supplements~* Allergy or sensitivity to spices. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of spices ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded~* Taking antibiotics or laxatives within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Mixed spices intervention group (Type: EXPERIMENTAL): healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
- placebo group (Type: PLACEBO_COMPARATOR): healthy participants consume placebo capsule containing 5 g of maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients \>18 years of age~* Double- or triple-vessel coronary artery disease~* Elective isolated first-time CABG~* Combined valve surgery + CABG~* Written informed consent~Exclusion Criteria:~* Renal failure (creatinine ≥ 200 µmol/L)~* Peripheral vascular disease affecting upper limbs~* Preoperative inotropic support~* Any kind of mechanical assist device~* Acute or recent (\<4 weeks) acute coronary syndromes~* Any PCI (\<6 weeks)~* Any reasons for preoperative cTnI elevation~* Emergency surgery~* Redo surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RIPC (Type: ACTIVE_COMPARATOR): Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
- Control (Type: PLACEBO_COMPARATOR): Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 28-day Repeat Dose Study of GSK573719

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A signed and dated written informed consent prior to study participation~* Males or females of non-childbearing potential~* 40 to 80 years of age~* COPD diagnosis~* 10 pack-years history or greater of cigarette smoking~* Post-bronchodilator FEV1/FVC ratio of 0.70 or less~* Post-bronchodilator FEV1 of 25 to 70% of predicted normal~Exclusion Criteria:~* Asthma~* Other significant respiratory disorders besides COPD, including alpha-1 deficiency~* Previous lung resection surgery~* Chest X-ray or CP scan showing clinically significant abnormalities not due to COPD~* Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of screening~* Hospitalization for COPD or pneumonia within 3 months of screening~* Any significant disease that would put subject at risk through study participation~* BMI greater than 35~* Pacemaker~* Significantly abnormal ECG or clinical lab finding (including Hepatitis B or C)~* Cancer~* Allergy or hypersensitivity to anticholinergics or inhaler excipients~* Diseases that would contraindicate the use of anticholinergics~* Use of oral corticosteroids within 6 weeks of screening~* Use of long-acting beta-agonists within 48 hours of screening~* Use of tiotropium within 14 days of screening~* Use of theophyllines or anti-leukotrienes within 48 hours of screening~* Use of short-acting bronchodilators within 4 to 6 hours of screening~* Use of investigational medicines within 30 days of screening~* Use of high dose inhaled corticosteroids~* Use of long-term oxygen therapy, CPAP or NIPPV~* Participation in acute phase of pulmonary rehabilitation program~* History of alcohol or drug abuse within 2 years prior to screening~* History of psychiatric disease limiting validity of consent~* Affiliation with the investigative site~* Previous use of GSK573719

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GSK573719 125mcg (Type: EXPERIMENTAL): 125mcg once-daily via novel dry powder inhaler
- GSK573719 250mcg (Type: EXPERIMENTAL): 250mcg once-daily via novel dry powder inhaler
- GSK573719 500mcg (Type: EXPERIMENTAL): 500mcg once-daily via novel dry powder inhaler
- Placebo (Type: PLACEBO_COMPARATOR): once-daily via novel dry powder inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~* Current primary diagnosis of bipolar I disorder, mania or mixed type~* Acute exacerbation of mania associated with bipolar disorder as defined by Mania Rating Scale score \>= 18~* Hospitalized no more than 7 days at time of Screening or in process of being admitted~* History of at least one prior manic or mixed episode within past 3 years, exclusive of the current episode. Prior manic or mixed episode must be separated from current episode by at least 2 months of sustained improvement~EXCLUSION CRITERIA~* History of schizophrenia or schizoaffective disorder~* Axis I (e.g., anxiety disorder), or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results~* Current manic or mixed episode is drug-induced or secondary to a medical disorder (e.g., AIDS, corticosteroids)~* Current manic or mixed episode is believed to be caused by antidepressant use (i.e., antidepressant-induced mania)~* Had first manic episode after age 60~* Has ever taken clozapine~* Has received depot neuroleptic medication within one inter-injection interval of first dose of study drug~* Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine or amphetamines~* History of active alcohol or substance dependence within past 3 months.~* History of failed treatment on adequate valproate therapy for bipolar disorder~* Has taken Depakote (DR or ER) regularly over the last 30 days~* Has serious violent, homicidal, or suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eribulin in HER2 Negative Metastatic BrCa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1~* Hormone receptor positive or hormone receptor negative HER2-negative disease~* Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)~* Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable~* No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy~* Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy~* Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia~* Agree to use adequate contraception for the duration of study participation~Exclusion Criteria:~* Pregnant or breastfeeding~* Prior treatment with eribulin~* Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study~* Clinically significant cardiovascular impairment~* Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases~* Pulmonary dysfunction requiring the use of oxygen~* Prior organ allograft requiring immunosuppression~* HIV positive on combination antiretroviral therapy~* Pre-existing grade 3 or 4 neuropathy~* Hypersensitivity to halichondrin B or halichondrin B chemical derivative~* Uncontrolled intercurrent illness~* Inability to read in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: HR+/HER2- (Type: EXPERIMENTAL): Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.
- Cohort 2: TNBC (Type: EXPERIMENTAL): Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily signed informed consent ;~* Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.~* Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies~* ESSDAI score ≥ 5.~Exclusion Criteria:~* Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and other autoimmune diseases;~* Abnormal laboratory parameters need to be excluded, including but not limited to:~* Immunosuppressive agents were used within 4 weeks prior to randomization.;~* The use of hydroxychloroquine was allowed during the trial, and the pre-randomized drug regimen was stable for less than 12 weeks;~* Use of biological agents for targeted therapy in the first 6 months of randomization;~* Treatment of primary Sjogren's syndrome with traditional Chinese medicine and proprietary Chinese medicine within 4 weeks before randomization;~* The use of saliva-stimulating drugs within 7 days prior to randomization;~* Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of the randomized pre-medication scheme is less than 4 weeks;~* Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before randomization;~* Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;~* Currently suffering from active hepatitis or severe liver lesions and history;~* Malignant tumor patients ;~* Combined with involvement of important organs or neuropathy;~* Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the shorter).~* Pregnant , lactating women and men or women who have birth plans during the research;~* Investigator considers candidates not appropriating for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RC18 240mg (Type: EXPERIMENTAL): None
- RC18 160 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high risk of stroke, or systemic embolism with at least one additional risk factor (i.e. previous ischemic stroke, TIA, or systemic embolism, left ventricular dysfunction, age \>=75 years, age \>=65 with either diabetes mellitus, history of coronary artery disease or hypertension)~Exclusion criteria~1. Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study~2. Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days~3. Conditions associated with an increased risk of bleeding~4. Contraindication to warfarin treatment~5. Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).~6. Plan to perform a pulmonary vein ablation or surgery for cure of the AF~7. Severe renal impairment (estimated creatinine clearance \<=30 mL/min)~8. Active infective endocarditis~9. Active liver disease~10. Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study~11. Anaemia (haemoglobin \<100g/L) or thrombocytopenia (platelet count \<100 x 109/L)~12. Patients who have developed transaminase elevations upon exposure to ximelagatran~13. Patients who have received an investigational drug in the past 30 days or are participating in another drug study~14. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)~15. Any known hypersensitivity to galactose if the warfarin used contains galactose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran dose 2 (Type: ACTIVE_COMPARATOR): twice a day
- Warfarin (Type: ACTIVE_COMPARATOR): once a day
- Dabigatran dose 1 (Type: ACTIVE_COMPARATOR): twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven diagnosis of multiple myeloma~* Patients must be enrolled in treatment with novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab)~* Patients must have Creatinine Clearance above 30 mL/min on the Day 1 of trial~* Patients must have given informed consent to participate in trial.~Exclusion Criteria:~* Contraindication to the use of one of the study drug/vaccines (including known hypersensitivity)~* Creatinine Clearance below 30 mL/min on the Day 1 of trial~* Psychiatric disorder or unable to understand or to follow the protocol directions~* Active bacterial, viral, fungal or protozoal infection on the Day 1 of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vaccination group (Type: EXPERIMENTAL): Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
- Standard prophylaxis (Type: ACTIVE_COMPARATOR): Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent for study participation obtained before undergoing any study-specific procedures~* Documented congenital FXIII deficiency that requires prophylactic treatment with a FXIII containing product.~* Males and females of any age with congenital FXIII deficiency.~* Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive~Exclusion Criteria:~* Diagnosis of acquired FXIII deficiency~* Administration of a FXIII-containing product, including blood transfusions or other blood products within 4 weeks prior to the planned Day 0~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Known or suspected to have antibodies towards FXIII~* Use of any other investigational medicinal product within 4 weeks prior to the Baseline Visit (Day 0)~* Positive result at screening for human immunodeficiency virus (HIV)~* Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration \>2.5 times the upper limit of normal~* Fibrinogen \< lower limit of normal~* Active bleeding~* Pregnant or breast-feeding~* Intention to become pregnant during the course of the study~* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study~* Surgical procedure anticipated during the study period~* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FXIII (Type: EXPERIMENTAL): All subjects treated with Factor XIII Concentrate (Human) (FXIII)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete